Trial Profile
A Phase I/II Study of Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 07 Mar 2024
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Gemcitabine (Primary) ; Nivolumab (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- 01 Mar 2024 Planned End Date changed from 30 Nov 2023 to 22 Dec 2024.
- 01 Mar 2024 Planned primary completion date changed from 30 Nov 2023 to 22 Dec 2024.
- 02 Sep 2022 Planned End Date changed from 30 Nov 2022 to 30 Nov 2023.